A 12-week Randomized, Patient and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate the Efficacy of LIK066 in Obese Patients With Non-alcoholic Steatohepatitis (NASH)
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2018
At a glance
- Drugs LIK 066 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 13 Jun 2018 Planned primary completion date changed from 13 Apr 2019 to 26 Sep 2019.
- 19 Oct 2017 Status changed from not yet recruiting to recruiting.
- 24 Jul 2017 Planned End Date changed from 10 Aug 2019 to 13 Apr 2019.